

11. Oh MS, Banerji MA, Carroll HJ. The mechanism of hyperchloremic acidosis during the recovery phase of diabetic ketoacidosis. *Diabetes*. 1981;30:310-3.
12. Helmersson-Karlqvist J, Höög Hammarström K, Palmberg K, Backman-Johansson C. Evaluation of Nova StatStrip and FreeStyle Precision Pro blood ketone tests using 3-hydroxybutyrate doped samples. *J Clin Lab Anal*. 2019 May;33(4):e22851. doi: 10.1002/jcla.22851.
13. Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T, et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. *Br Med J*. 1979 Nov 17;2(6200):1257-9. doi: 10.1136/bmj.2.6200.1257.
14. Palmer BF, Clegg DJ. Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. *N Engl J Med*. 2015 Aug 6;373(6):548-59.
15. Kamel KS, Halperin ML. Acid-base problems in diabetic ketoacidosis. *N Engl J Med*. 2015;372:1969-70.
16. Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. *J Biol Chem*. 2020;295:14379-90.
17. Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. *Clin J Am Soc Nephrol*. 2021;16:1284-91.
18. Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis. *BMC Endocr Disord*. 2023 Apr 14;23(1):81. doi: 10.1186/s12902-023-01339-w.
19. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. *Pharmacotherapy*. 2017;37:187-94.
20. Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. *Nat Commun*. 2019;10:548.
21. Adeva-Andany MM, Funcasta-Calderón R, Fernández-Fernández C, Castro-Quintela E, Carneiro-Freire N. Metabolic effects of glucagon in humans. *J Clin Transl Endocrinol*. 2018 Dec 20;15:45-53.
22. Johnston DG, Alberti KG. Hormonal control of ketone body metabolism in the normal and diabetic state. *Clin Endocrinol Metab*. 1982 Jul;11(2):329-61.
23. Jones BJ, Tan T, Bloom SR. Minireview: Glucagon in stress and energy homeostasis. *Endocrinology*. 2012 Mar;153(3):1049-54.
24. Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. *J Diabetes Complications*. 2016 Aug;30(6):1162-6.
25. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat Med*. 2015 May;21(5):512-7.
26. Pedersen MG, Ahlstedt I, El Hachmane MF, Göpel SO. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. *Sci Rep*. 2016 Aug 18;6:31214.
27. Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, et al. SGLT2 is not expressed in pancreatic  $\alpha$ - and  $\beta$ -cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. *Mol Metab*. 2020 Dec;42:101071.
28. Palmer BF, Clegg DJ. Electrolyte Disturbances in Patients with Chronic Alcohol-Use Disorder. *N Engl J Med*. 2017 Oct 5;377(14):1368-1377. doi: 10.1056/NEJMr1704724.
29. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. *Diabetes Metab Res Rev*. 2017 Nov;33(8):10.1002/dmrr.2924. doi: 10.1002/dmrr.2924. Epub 2017 Sep 29. PMID: 28736981; PMCID: PMC5950709.
30. Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, et al. A role for tubular  $\text{Na}^+/\text{H}^+$  exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. *Am J Physiol Renal Physiol*. 2020 Oct 1;319(4):F712-F728. doi: 10.1152/ajprenal.00264.2020. Epub 2020 Sep 7. PMID: 32893663; PMCID: PMC7642886.
31. Hall JE, Hall ME, Guyton AC. Guyton and Hall textbook of medical physiology. Elsevier 2021.
32. Halperin ML, Vinay P, Gougoux A, Pichette C, Jungas RL. Regulation of the maximum rate of renal ammoniogenesis in the acidotic dog. *Am J Physiol*. 1985;248: F607-15.
33. Lemieux G, Pichette C, Vinay P, Gougoux A. Cellular mechanisms of the antiammoniogenic effect of ketone bodies in the dog. *Am J Physiol*. 1980 Nov;239(5):F420-6.
34. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*. 2014 Feb 4;129(5):587-97.
35. Vinay P, Lemieux G, Cartier P, Ahmad M. Effect of fatty acids on renal ammoniogenesis in vivo and in vitro studies. *Am J Physiol*. 1976;231:880-7.
36. Lemieux G, Baverel G, Vinay P, Gougoux A. Effect of fluoroacetate on the inhibitory action of ketone bodies and fatty acids on renal ammoniogenesis. *Am J Physiol*. 1979 Jul;237(1):F7-13.
37. Lemieux G, Vinay P, Robitaille P, Plante GE, Lussier Y, Martin P. The effect of ketone bodies on renal ammoniogenesis. *J Clin Invest*. 1971 Sep;50(9):1781-91.
38. Goldstein L, Boylan JM, Schröck H. Adaptation of renal ammonia production in the diabetic ketoacidotic rat. *Kidney Int*. 1980;17:57-65.
39. Story DA. Bench-to-bedside review: a brief history of clinical acid-base. *Crit Care Lond Engl*. 2004;8(4):253-258. doi:10.1186/cc2861
40. Warming-Larsen A. Renal excretion of ketone bodies. II. *Acta Med Scand*. 1952;144:197-200.
41. Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, et al. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. *J Crit Care*. 2012 Apr;27(2):138-45. doi: 10.1016/j.jccr.2012. 01. 007. PMID: 22440386.
42. Catahah JA, Polintan ET, Casimiro M, Notarte KI, Velasco JV, Ver AT, et al. Balanced electrolyte solutions versus isotonic saline in adult patients with diabetic ketoacidosis: A systematic review and meta-analysis. *Heart Lung*. 2022 Jul-Aug;54:74-79. doi: 10.1016/j.hrtlng.2022. 03. 014. Epub 2022 Mar 28. PMID: 35358905.
43. Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. *Am J Emerg Med*. 2011;29(6):670-674. doi:10.1016/j.ajem.2010. 02. 004.
44. Self WH, Evans CS, Jenkins CA, Brown RM, Casey JD, Collins SP, et al; Pragmatic Critical Care Research Group. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis: A Subgroup Analysis of Cluster Randomized Clinical Trials. *JAMA Netw Open*. 2020 Nov 2;3(11):e2024596. doi: 10.1001/jamanetworkopen.2020.24596. PMID: 33196806; PMCID: PMC7670314.
45. FDA approves label changes to SGLT2 inhibitors regarding temporary discontinuation of medication before scheduled surgery. <https://www.fda.gov/drugs/drug-safety-too-much-acid-blood-and-serious>. Accessed March 23, 2020.
46. Bobrowski D, Kumar R, Wu PE, Lapointe-Shaw L. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy. *Clin Case Rep*. 2021 Nov 9;9(11):e05057.
47. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.
48. Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. *Annu Rev Physiol*. 2021;83(1):503-528. doi:10.1146/annurev-physiol-031620-095920.